{"name":"Taisho Pharmaceutical R&D Inc.","slug":"taisho-pharmaceutical-r-d-inc","ticker":"","exchange":"","domain":"","description":"Taisho Pharmaceutical R&D Inc. is a Japanese pharmaceutical company focused on the research and development of innovative drugs, particularly in oncology. The company has a pipeline of seven drug candidates, with a focus on early-stage clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"TS-121","genericName":"TS-121","slug":"ts-121","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"TS-121","genericName":"TS-121","slug":"ts-121","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxNY0paTlREYU1FOW4tOC1DNlFLM0tjaWQwcXVmSEpPN1ZoSndCTlU2eXhpUXRlbnpQMjM4OEZfbmNybWVIdFhaeTIwdTNxV21xay0zQVFUMzNMUnFMU2ZmcjQ1RVRsNEljUTJkdnJBTFZwMGVBNTdmOTU1b3hTcGZnbXo5MjYxNkxTeGJWT2FUNjBZQ1lHZkIycFZIekFEVXp3Szk2ZVdSNTAyYzUtVFVVWk9PNGQ3TGxHRjdDaFA5N21obUZDV3VIVks2QVMyOXhXdVJZMjFTVk1ZZkZwdXpNeEZNcGJJanlvTmM1TlVVT0ZaRG9wVXlrdDV3cFRsem9kOE1yeVFXdXFNdw?oc=5","date":"2026-03-30","type":"deal","source":"Business Wire","summary":"Biocytogen Grants Taisho Pharmaceutical a License to its RenNano - Business Wire","headline":"Biocytogen Grants Taisho Pharmaceutical a License to its RenNano","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxNeWR4QkJHMnRoRXlnS0NJWkt2NFBCc1VRRUxWalBLWnBVYmJ6enNuWnpwYmJ4NURHdWlQamV6dWJmNTlmeUlYeER5Zmc5MVgxQVlOV25laEgwb1otSVFrUjZXU1o5bGFjZEc4cGdic0RNSUNHYkZWU0hfenp1Q3cwVmNVOElTRXYyY2hfMnZPUkFYbW9VelVaVE16Y3ZYNW5YVWstMnpYU0RCbGVic0ZFcFNTQ09nSUlvZVpxbV9NZVppaHdmUDlqd2l4eXdyZDJk?oc=5","date":"2026-03-30","type":"deal","source":"National Today","summary":"Biocytogen Grants Taisho Pharmaceutical License to RenNano® Antibody Platform - National Today","headline":"Biocytogen Grants Taisho Pharmaceutical License to RenNano® Antibody Platform","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNb3M0ek14cGtWaVBXdlNIbDR5a1p2NzdtQkFYR09zNm9xazVMZlY1MnpNcGo0YkhVNnNGbFlTaFZFQV90V25fal9MWkhxWmtMQm5RenpMLVNWN05MZUpIZTF4Z1BfOXluaHVlbXNUS3lZWUR6ek1yS01iWng0NXUtTEQ3YTR6bzFENGJKVHBOQmk3LVBDOWU1cDI2VjNVWXAwUWgtcS14azF4Z0JjQ2pCUWk0WUpobnRIaUZrNDBfdWhrc003eTE4YTJBZmtvN00?oc=5","date":"2026-02-10","type":"deal","source":"The Hearing Review","summary":"AudioCardio Partners with Taisho Pharmaceuticals to Launch Hearing App in Japan - The Hearing Review","headline":"AudioCardio Partners with Taisho Pharmaceuticals to Launch Hearing App in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE9sUFVGQTlTaXJSeE54eTZsQk5rRnBONXNEeE1VQ0dkbmxEa2hjTEJLcUt1amtQdjVIR2xEOHl4YjA2SmdCbEJIU2VmazBLYlpuZUswN0Q2SnpfMTQ2S0k1cUotdllWaTBO?oc=5","date":"2025-10-09","type":"regulatory","source":"Wiley Online Library","summary":"Efficacy of luseogliflozin for renal function preservation in patients with type 2 diabetes mellitus and impaired renal function: A randomized open-label clinical trial (RESOLUTION study) - Wiley Onli","headline":"Efficacy of luseogliflozin for renal function preservation in patients with type 2 diabetes mellitus and impaired renal ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNTWc4NS01V0JwaDlqV0ZIbFBNbEZneDI0b3E2YkpjckpVV3JuNUMtSjk3M3pNMHFwM05ERW9zMlBBTmtoeTNuZVI0dFdzb2JKY2J4ZzFOMXhYMzRVakZ2aWYtMVlpQnBUTTc0WlRKQ0wzVFVNV0ZEZHZiMFQ5RElPY2hBRVNCR1BWdm1oTEJwcXFsVklnTTZwUWFlc0x0aVlzemJUNUlQVXhLNEZCbXJuZmhfT253cTZr?oc=5","date":"2024-09-12","type":"pipeline","source":"Asia Research News |","summary":"BMI’s relation to cancer therapy mortality risks not so straightforward - Asia Research News |","headline":"BMI’s relation to cancer therapy mortality risks not so straightforward - Asia Research News |","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNY2czbEZialdPWUZRREpLTVNXVWNqR1p3ZVZCNTRvM2QzMVBWT2hrdzFscmd1UVUtRFZ6clZvSDJOTTZvcDZ5X2tMWnhGblBuckQ3MjZwUzZ0aHlUaWp6Sm4wUXV4VzBaZURYbm5wRy1qc0drQW5EeXdsYjF4NnBjWTVnMW0?oc=5","date":"2024-07-15","type":"deal","source":"pharmaphorum","summary":"Investors take issue with Taisho Pharma’s buyout price - pharmaphorum","headline":"Investors take issue with Taisho Pharma’s buyout price","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOZktDTlM4Nk1yU1A0R2RTNjEwMXZHZ1JjbzlURUV2X0s5bzA4RGhYNncwdzFxZm9kUHB2cHM2UjhUMzgzRk8tWE9GdnlLLUdoTm10eEhQSlNXYVRZQlpJZ2V6V3pWY0RlU0RjdUVTSVJUZmNabGxDVFpNZmdqMDh3dGFLbWRqbFNQQ3psak5WNA?oc=5","date":"2024-02-01","type":"pipeline","source":"Frontiers","summary":"Mechanisms of Perceived Treatment Assignment and Subsequent Expectancy Effects in a Double Blind Placebo Controlled RCT of Major Depression - Frontiers","headline":"Mechanisms of Perceived Treatment Assignment and Subsequent Expectancy Effects in a Double Blind Placebo Controlled RCT ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPenE3d2dOSEdoRGY2MkFRbnBGUXRUYXoySnpXeUNfNnVJWnRoZVZRSWViNURZSU1sSjA3YTZNenpoazc2dU1vMWtFWXR6M0ZWRkg4aEZzV3N5enlFZENWeVNZUVBJZzRabzF2UzJ2QVRMQ3NGUXlseDh0Y2ZkTjdXd1dKbklwZ01L?oc=5","date":"2023-12-06","type":"deal","source":"pharmaphorum","summary":"Taisho says $5bn management buyout will rev up business - pharmaphorum","headline":"Taisho says $5bn management buyout will rev up business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQaERxTHBEUW5wV1V3S29QbDA1c0xoUUQ4WW5OTDZMR2ZtRklkWWtDNlNNNjNoMjB3dEc4NFp0U2xNcXdhMzE5amVZUXFQVlJnV3BoeG5odDBhdjlVOG96aThQRVh0THFJc3BjcFZQUEJ1UEN4ZFJDMVYzRkIxa1MwT0lUNGhRYzFab2laRm1Db0J5OGNGM0E?oc=5","date":"2021-07-03","type":"patent","source":"Generics and Biosimilars Initiative","summary":"Global generics: time for consolidation and expansion - Generics and Biosimilars Initiative","headline":"Global generics: time for consolidation and expansion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE1hODgxMWoxMm9WU0N1OXA0YmVON000MjdmNGRrWGE4N1MyaDNvblV4UDNuMmQ3Z1VvcTRJOHI4YTg3SjBSOURsOUJ0NXdDMWRYaXh0Q3lnYlFZblk?oc=5","date":"2020-10-15","type":"deal","source":"EurekAlert!","summary":"Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery - EurekAlert!","headline":"Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery - EurekAlert!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxOdGphNm1uWVNEOU50SU0xX0JOeDZGQUpGWmp1d1p0bUJGNTRfVmFlSk9RejZMN3pJTXhHRzJpMGNmNENVbEJseWhGQ0xZZDhlUEtpVFdCZGh6RVluN0pzS09adEp5YmViYWtPRXFlRTEzZ19JWDV3WnRQUVFZX2Q3Q3FCeXhCOXB2V014QjhndkprY3NnUWhZQ3RHdzFLRG5Gc0xMMS1Gdm1hbGVPTkFjMDhvUmhWRTVMM1FISXhOTE9Ga0hDQ0twY3pfRmxpdFpQbFRyZGVqMXE1LW9GeFRFalNoU0s0ZHo5bVo1VTBzaDExODdlNDZoQTBJcklvcHNDbHk1Q1B5cHdZV1pRMW9zU0R3SQ?oc=5","date":"2019-04-16","type":"pipeline","source":"DC Advisory","summary":"DC Advisory advised Taisho Pharmaceutical on a dual stage acquisition of 51% stake in Duoc Hau Giang Pharmaceutical JSC - DC Advisory","headline":"DC Advisory advised Taisho Pharmaceutical on a dual stage acquisition of 51% stake in Duoc Hau Giang Pharmaceutical JSC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPRUU2cXR6UVdSR2U5ZDJTZlBpLU50a09JcHJMdE1kMmJUVXJxNVJHUUZ0SkRDNzN2dWhPdC1jdzU3a1lsWDRDRjJSZmNRZnlkTWNaSkFhcVBGSWlud3dxUnBmenVFS3AyNGpHakp2eXZOdEpvbUZVamtnNUNHOUI2Q1A3d2lROVc5aFdSRHFTZm1HTkpqQkd0dHI2SVB6eXJfMWNjMkU3Y2R1cFlLRE1rOU5vc2tnY1oy?oc=5","date":"2018-12-19","type":"pipeline","source":"Citeline News & Insights","summary":"Bristol-Myers Squibb Sells French Consumer Health Unit UPSA To Taisho For $1.6bn - Citeline News & Insights","headline":"Bristol-Myers Squibb Sells French Consumer Health Unit UPSA To Taisho For $1.6bn - Citeline News & Insights","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}